Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers
Lectura recomendada por el Dr. Mauricio Luongo. Conferencia 2024: “Presente de los tratamientos con Inmunoradioterapia." Autores: David A Palma, Robert Olson, Stephen Harrow, Stewart Gaede et al. Fuente: Lancet 2019; 393: 2051–58. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial Descargar [...]
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer
Lectura recomendada por el Dr. Mauricio Luongo. Conferencia 2024: “Presente de los tratamientos con Inmunoradioterapia." Autores: Chiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian et al. Fuente: Lancet 2019; 393: 2051–58. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] [...]
The Promise of Combining Radiation Therapy With Immunotherapy
Lectura recomendada por el Dr. Mauricio Luongo. Conferencia 2024: “Presente de los tratamientos con Inmunoradioterapia." Autores: Justin C. Jagodinsky, Paul M. Harari and Zachary S. Morris. Fuente: Int J Radiation Oncol Biol Phys, Vol. 108, No. 1, pp. 6e16, 2020 The Promise of Combining Radiation Therapy With Immunotherapy Descargar
Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study
Lectura recomendada por el Dr. Mauricio Luongo. Conferencia 2024: “Presente de los tratamientos con Inmunoradioterapia." Autores: Rodolfo Chicas-Sett, Juan Zafra, Delvys Rodriguez-Abreu et al. Fuente: Int J Radiation Oncol Biol Phys, Vol. 114, No. 4, pp. 655−665, 2022 Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study [...]
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
Lectura recomendada por el Dr. Santiago Fontes. Conferencia 2024: “Inmunoterapia contra el cáncer; un nuevo paradigma” Autores: Tianyu Tang, Xing Huang, Gang Zhang, Zhengtao Hong, Xueli Bai and Tingbo Liang. Fuente: Signal Transduction and Targeted Therapy (2021) Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy Descargar
Cancer immunotherapy: Pros, cons and beyond
Lectura recomendada por el Dr. Santiago Fontes. Conferencia 2024: “Inmunoterapia contra el cáncer; un nuevo paradigma” Autores: Shuzhen Tana, Dongpei Lib, Xiao Zhu. Fuente: Biomedicine & Pharmacotherapy 124 (2020) Cancer immunotherapy: Pros, cons and beyond Descargar